Are IRBs Inspected by FDA?

BACK TO FAQs

FDA regulations generally require IRB review and approval of research involving FDA regulated products (e.g., investigational drugs, biological products, and medical devices) (21 CFR 56).  

FDA developed its Bio Research Monitoring (BIMO) Program to ensure the protection of the rights, welfare, and safety of human subjects and the quality and integrity of data submitted to the Agency. Among other things, the FDA BIMO Program involves site visits to IRBs, clinical investigators, sponsors, monitors, contract research organizations, nonclinical (animal) laboratories, and bioequivalence analytical laboratories. This document addresses site visits to IRBs that review clinical investigations that are regulated by FDA under 21 USC 355(i) and 21 USC 360(j) and clinical investigations that support applications for research or marketing permits for products regulated by FDA.

About the Author
Proxima CRO Team
Bufo Areh
Clinical Research Associate

Nwabufo obtained his B.Sc. in Biotechnology with a minor in Business Administration from the Richard Stockton University, New Jersey. Nwabufo has over four years of global experience in a variety of therapeutic areas, including cardiovascular, oncology, ophthalmology, infectious diseases, CNS, and metabolic diseases as a clinical research associate.

Related FAQs:
More Questions? We're here to help!
SPEAK WITH A SPECIALIST